LBA13 Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (Pts) with HR+/HER2− early breast cancer (EBC): 4-year outcomes from the NATALEE trial - Fasching, P A; Stroyakovskiy, D; Yardley, D (Ann Oncol, 2024)
et al.